Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
Nat Med
    December 2025
  1. EDISON P, Femminella GD, Ritchie C, Nowell J, et al
    Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.
    Nat Med. 2025 Dec 1. doi: 10.1038/s41591-025-04106.
    >> Share

    November 2025
  2. JANELIDZE S
    A new blood biomarker for Alzheimer's disease.
    Nat Med. 2025 Nov 3. doi: 10.1038/s41591-025-04028.
    >> Share

  3. YAU WW, Kirn DR, Rabin JS, Properzi MJ, et al
    Physical activity as a modifiable risk factor in preclinical Alzheimer's disease.
    Nat Med. 2025 Nov 3. doi: 10.1038/s41591-025-03955.
    >> Share

  4. LIU Y, Gu X, Li Y, Wang F, et al
    Interplay of genetic predisposition, plasma metabolome and Mediterranean diet in dementia risk and cognitive function.
    Nat Med. 2025;31:3790-3800.
    >> Share

    October 2025

  5. A brief digital cognitive test improves Alzheimer's disease detection.
    Nat Med. 2025 Oct 16. doi: 10.1038/s41591-025-04024.
    >> Share

    September 2025
  6. TIDEMAN P, Karlsson L, Strandberg O, Calling S, et al
    Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers.
    Nat Med. 2025 Sep 15. doi: 10.1038/s41591-025-03965.
    >> Share

  7. ALI M, Erabadda B, Chen Y, Xu Y, et al
    Author Correction: Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.
    Nat Med. 2025 Sep 2. doi: 10.1038/s41591-025-03970.
    >> Share

    August 2025
  8. SHVETCOV A, Johnson ECB, Winchester LM, Walker KA, et al
    APOE epsilon4 carriers share immune-related proteomic changes across neurodegenerative diseases.
    Nat Med. 2025;31:2590-2601.
    >> Share

  9. IMAM F, Saloner R, Vogel JW, Krish V, et al
    The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.
    Nat Med. 2025;31:2556-2566.
    >> Share

  10. OH HS, Le Guen Y, Rappoport N, Urey DY, et al
    Plasma proteomics links brain and immune system aging with healthspan and longevity.
    Nat Med. 2025;31:2703-2711.
    >> Share

    July 2025
  11. CHUI DH, Tanahashi H, Ozawa K, Ikeda S, et al
    Editorial Expression of Concern: Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation.
    Nat Med. 2025 Jul 25. doi: 10.1038/s41591-025-03903.
    >> Share

  12. ALI M, Erabadda B, Chen Y, Xu Y, et al
    Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.
    Nat Med. 2025 Jul 15. doi: 10.1038/s41591-025-03833.
    >> Share

  13. GATES B
    Global collaboration is key to decoding Alzheimer's disease.
    Nat Med. 2025 Jul 15. doi: 10.1038/d41591-022-00044.
    >> Share

  14. COLONNA M, Holtzman DM
    Rethinking TREM2 as a target for Alzheimer's disease after the INVOKE-2 trial failure.
    Nat Med. 2025 Jul 2. doi: 10.1038/s41591-025-03816.
    >> Share

    June 2025
  15. SELKOE DJ
    In Alzheimer's disease, dimers do the damage.
    Nat Med. 2025;31:1727.
    >> Share

    April 2025

  16. Cerebrospinal fluid biomarker predicts dementia onset and progression in Alzheimer's disease.
    Nat Med. 2025 Apr 28. doi: 10.1038/s41591-025-03700.
    >> Share


  17. Microglia drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Apr 22. doi: 10.1038/s41591-025-03677.
    >> Share

  18. O'LEARY K
    Anti-amyloid could help prevent genetic form of Alzheimer's disease.
    Nat Med. 2025 Apr 17. doi: 10.1038/d41591-025-00026.
    >> Share

  19. PALMQVIST S, Warmenhoven N, Anastasi F, Pilotto A, et al
    Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.
    Nat Med. 2025 Apr 9. doi: 10.1038/s41591-025-03622.
    >> Share

  20. ANDRIEU S, Bateman RJ, Bereczki E, Bose N, et al
    Harnessing artificial intelligence to transform Alzheimer's disease research.
    Nat Med. 2025 Apr 1. doi: 10.1038/s41591-025-03632.
    >> Share

    March 2025
  21. HORIE K, Salvado G, Koppisetti RK, Janelidze S, et al
    Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease.
    Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03617.
    >> Share

  22. OH HS, Urey DY, Karlsson L, Zhu Z, et al
    A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease.
    Nat Med. 2025 Mar 31. doi: 10.1038/s41591-025-03565.
    >> Share

  23. VAN OLST L, Simonton B, Edwards AJ, Forsyth AV, et al
    Author Correction: Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Mar 28. doi: 10.1038/s41591-025-03664.
    >> Share

  24. GRANDE G, Valletta M, Rizzuto D, Xia X, et al
    Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.
    Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03605.
    >> Share

  25. RAJJI TK, Baksh SN, Shade DM, Ismail Z, et al
    Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.
    Nat Med. 2025 Mar 25. doi: 10.1038/s41591-025-03569.
    >> Share

  26. RASH BG, Ramdas KN, Agafonova N, Naioti E, et al
    Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
    Nat Med. 2025 Mar 10. doi: 10.1038/s41591-025-03559.
    >> Share

  27. VAN OLST L, Simonton B, Edwards AJ, Forsyth AV, et al
    Microglial mechanisms drive amyloid-beta clearance in immunized patients with Alzheimer's disease.
    Nat Med. 2025 Mar 6. doi: 10.1038/s41591-025-03574.
    >> Share

  28. MOUTINHO S
    Women twice as likely to develop Alzheimer's disease as men - but scientists do not know why.
    Nat Med. 2025;31:704-707.
    >> Share

  29. DUFF EP, Zetterberg H, Heslegrave A, Dehghan A, et al
    Plasma proteomic evidence for increased beta-amyloid pathology after SARS-CoV-2 infection.
    Nat Med. 2025;31:797-806.
    >> Share

    February 2025
  30. ISLAM T, Hill E, Abrahamson EE, Servaes S, et al
    Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease.
    Nat Med. 2025 Feb 10. doi: 10.1038/s41591-024-03400.
    >> Share

  31. LLIBRE-GUERRA JJ, Fernandez MV, Joseph-Mathurin N, Bian S, et al
    Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia.
    Nat Med. 2025 Feb 10. doi: 10.1038/s41591-025-03494.
    >> Share

    December 2024
  32. MOGUILNER S, Baez S, Hernandez H, Migeot J, et al
    Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations.
    Nat Med. 2024;30:3646-3657.
    >> Share

    July 2024
  33. FORTEA J, Vaque-Alcazar L, Pegueroles J, Alcolea D, et al
    Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03159.
    >> Share

  34. PAPPALETTERA C, Carrarini C, Cappa S, Caraglia N, et al
    Challenges to identifying risk versus protective factors in Alzheimer's disease.
    Nat Med. 2024 Jul 18. doi: 10.1038/s41591-024-03158.
    >> Share

  35. ROSENZWEIG N, Kleemann KL, Rust T, Carpenter M, et al
    Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease.
    Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03122.
    >> Share

    June 2024
  36. JACK CR JR, Andrews SJ, Beach TG, Buracchio T, et al
    Revised criteria for the diagnosis and staging of Alzheimer's disease.
    Nat Med. 2024 Jun 28. doi: 10.1038/s41591-024-02988.
    >> Share

  37. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 Jun 17. doi: 10.1038/s41591-024-03127.
    >> Share

    May 2024
  38. SHANKS HRC, Chen K, Reiman EM, Blennow K, et al
    p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.
    Nat Med. 2024 May 17. doi: 10.1038/s41591-024-02977.
    >> Share

  39. FORTEA J, Pegueroles J, Alcolea D, Belbin O, et al
    APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02931.
    >> Share

  40. XU Q, Liang Z, Huang Y
    APOE4 homozygosity is a new genetic form of Alzheimer's disease.
    Nat Med. 2024 May 6. doi: 10.1038/s41591-024-02923.
    >> Share

    March 2024
  41. O'LEARY K
    A timeline of biomarker changes before Alzheimer's disease.
    Nat Med. 2024 Mar 15. doi: 10.1038/d41591-024-00018.
    >> Share

    February 2024
  42. BARTHELEMY NR, Salvado G, Schindler S, He Y, et al
    Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests.
    Nat Med. 2024 Feb 21. doi: 10.1038/s41591-024-02869.
    >> Share

    January 2024
  43. JUCKER M, Walker LC
    Evidence for iatrogenic transmission of Alzheimer's disease.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02768.
    >> Share

  44. BANERJEE G, Farmer SF, Hyare H, Jaunmuktane Z, et al
    Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone.
    Nat Med. 2024 Jan 29. doi: 10.1038/s41591-023-02729.
    >> Share

  45. O'LEARY K
    Modeling real-world data to repurpose drugs for Alzheimer's disease.
    Nat Med. 2024 Jan 18. doi: 10.1038/d41591-024-00003.
    >> Share

    December 2023
  46. O'LEARY K
    Positive results in Alzheimer's disease trials.
    Nat Med. 2023;29:2973.
    >> Share

    November 2023
  47. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Author Correction: Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Nov 20. doi: 10.1038/s41591-023-02718.
    >> Share

    October 2023
  48. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Author Correction: Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02639.
    >> Share

    September 2023
  49. LONGO FM, Massa SM
    Senolytic therapy for Alzheimer's disease.
    Nat Med. 2023 Sep 27. doi: 10.1038/s41591-023-02541.
    >> Share

  50. GONZALES MM, Garbarino VR, Kautz TF, Palavicini JP, et al
    Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.
    Nat Med. 2023 Sep 7. doi: 10.1038/s41591-023-02543.
    >> Share

  51. SELF WK, Holtzman DM
    Emerging diagnostics and therapeutics for Alzheimer disease.
    Nat Med. 2023 Sep 4. doi: 10.1038/s41591-023-02505.
    >> Share

    August 2023

  52. Events in the brain during the evolution of Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02477.
    >> Share

  53. JOHNSON ECB, Bian S, Haque RU, Carter EK, et al
    Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.
    Nat Med. 2023 Aug 7. doi: 10.1038/s41591-023-02476.
    >> Share


  54. A fluid biomarker accurately detects tau aggregate pathology in Alzheimer's disease.
    Nat Med. 2023 Aug 2. doi: 10.1038/s41591-023-02468.
    >> Share

  55. PALMQVIST S, Rossi M, Hall S, Quadalti C, et al
    Cognitive effects of Lewy body pathology in clinically unimpaired individuals.
    Nat Med. 2023;29:1971-1978.
    >> Share

  56. QUADALTI C, Palmqvist S, Hall S, Rossi M, et al
    Clinical effects of Lewy body pathology in cognitively impaired individuals.
    Nat Med. 2023;29:1964-1970.
    >> Share

    July 2023
  57. O'LEARY K
    Putting the brakes on Alzheimer's disease.
    Nat Med. 2023 Jul 31. doi: 10.1038/d41591-023-00067.
    >> Share

  58. HORIE K, Salvado G, Barthelemy NR, Janelidze S, et al
    CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.
    Nat Med. 2023 Jul 13. doi: 10.1038/s41591-023-02443.
    >> Share

  59. SANCHEZ VELA P, Trowbridge JJ, Levine RL
    Clonal hematopoiesis, aging and Alzheimer's disease.
    Nat Med. 2023 Jul 4. doi: 10.1038/s41591-023-02406.
    >> Share

    June 2023
  60. BOUZID H, Belk JA, Jan M, Qi Y, et al
    Clonal hematopoiesis is associated with protection from Alzheimer's disease.
    Nat Med. 2023 Jun 15. doi: 10.1038/s41591-023-02397.
    >> Share

    May 2023
  61. BELLAVER B, Povala G, Ferreira PCL, Ferrari-Souza JP, et al
    Astrocyte reactivity influences amyloid-beta effects on tau pathology in preclinical Alzheimer's disease.
    Nat Med. 2023 May 29. doi: 10.1038/s41591-023-02380.
    >> Share

  62. LJUBENKOV PA, Rabinovici GD
    Silencing tau to treat early Alzheimer's disease.
    Nat Med. 2023 May 17. doi: 10.1038/s41591-023-02357.
    >> Share

  63. LOPERA F, Marino C, Chandrahas AS, O'Hare M, et al
    Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man.
    Nat Med. 2023 May 15. doi: 10.1038/s41591-023-02318.
    >> Share

    April 2023
  64. MUMMERY CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, et al
    Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
    Nat Med. 2023 Apr 24. doi: 10.1038/s41591-023-02326.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016